Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors

Drug Testing and Analysis

Volumn 4, Issue 9, 2012, Pages 692-700

  Okano, Masato ^a   Nishitani, Yasunori ^a   Sato, Mitsuhiko ^a   Kageyama, Shinji ^a  

^a LSI MEDIENCE CORPORATION   (Japan)

Author keywords

Doping; GH isoform; GHRH, IGF 1; Growth hormone; WADA

Indexed keywords

PHYSIOLOGY;

ANALYTICAL METHOD; FALSE POSITIVE; GHRH, INSULIN-LIKE GROWTH FACTOR-1; GROWTH FACTOR; GROWTH HORMONE ISOFORM; GROWTH HORMONES; INSULIN-LIKE GROWTH FACTOR-1; ISOFORMS; WORLD ANTI-DOPING AGENCY;

IMMUNOLOGY;

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING HORMONE[1-44]; HUMAN GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; SOMATORELIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHLETE; CLINICAL EFFECTIVENESS; DOPING; FEMALE; GROWTH HORMONE ISOFORM DIFFERENTIAL IMMUNOASSAY; HUMAN; IMMUNOASSAY; JAPANESE; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 84866755834     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1385     Document Type: Article

References (28)

1. L. E. Theill, M. Karin Transcriptional control of GH expression and anterior pituitary development. Endocr. Rev. 1993, 14, 670.
2. P. A. Kelly, J. Djiane, M. C. Postel-Vinay, M. Edery The prolactin/growth hormone receptor family. Endocr. Rev. 1991, 12, 235.
3. J. I. Jones, D. R. Clemmons Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16, 3.
4. R. G. Smith Development of growth hormone secretagogues. Endocr. Rev. 2005, 26, 346.
5. WADA. The 2012 Prohibited List. Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf [11 February 2012].
6. Z. Wu, M. Bidlingmaier, R. Dall, C. J. Strasburger Detection of doping with human growth hormone. Lancet 1999, 353, 895.
7. M. Bidlingmaier, J. Suhr, A. Ernst, Z. Wu, A. Keller, C. J. Strasburger, et al. High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin. Chem. 2009, 55, 445.
8. WADA. Guidelines for application of hGH Isoform differential immunoassays, V 1.0, June 2010. Available at: http://www.wada-ama.org/Documents/Resources/Guidelines/WADA_Guidelines_hGH%20Differential%20Immunoassays_EN_June10.pdf [11 February 2012].
9. WADA. 2009 Laboratory Statistics. Available at: http://www.wada-ama.org/Documents/Science_Medicine/Anti-Doping_Laboratories/Lab_Statistics/WADA_2009_LaboratoryStatisticsReport_Final.pdf [11 February 2012].
10. WADA. 2010 Laboratory Statistics. Available at: http://www.wada-ama.org/Documents/Resources/Statistics/Laboratory_Statistics/WADA_2010_Laboratory_Statistics_Report.pdf [11 February 2012].
11. G. Gmeiner, C. Reichel, R. Kulovics, V. Scheiblhofer Defending Dynepo detection. Drug Test. Anal. 2010, 2, 526.
12. M. Kohler, A. Gotzmann, C. Görgens, U. Flenker, M. Thevis, W. Schänzer Comparison of hGH serum concentrations of Caucasian and African top athletes: an ethnicity study, in Recent Advances in Doping Analysis (18), (Eds: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck ). Sportverlag Strauß, Köln, 2010, pp. 196.
13. M. Okano, Y. Nishitani, M. Sato, A. Ikekita, S. Kageyama Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects. Drug Test. Anal. 2010, 2, 548.
14. J. Jing, S. Yang, X. Zhou, C. He, L. Zhang, Y. Xu, et al. Detection of doping with rhGH: excretion study with WADA-approved kits. Drug Test. Anal. 2011, 3, 784.
15. J. A. Kanaley, M. M. Weatherup-Dentes, E. B. Jaynes, M. L. Hartman Obesity attenuates the growth hormone response to exercise. J. Clin. Endocrinol. Metab. 1999, 84, 3156.
16. J. D. Wallace, R. C. Cuneo, M. Bidlingmaier, P. A. Lundberg, L. Carlsson, C. L. Boguszewski, et al. The response of molecular isoforms of growth hormone to acute exercise in trained adult males. J. Clin. Endocr. Metab. 2001, 86, 200.
17. P. Kaliszewski, D. Michalak, A. Pokrywka, D. Kwiatkowska Validation of differential immunoassays of hGH isoforms; KIT 1 and 2, in Recent Advances in Doping Analysis (17), (Eds: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck ). Sportverlag Strauß, Köln, 2009, pp. 297.
18. R. I. Holt Detecting growth hormone abuse in athletes. Drug Test. Anal. 2009, 1, 426.
19. M. Thevis, F. Wilkens, H. Geyer, W. Schänzer Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes. Rapid Commun. Mass Spectrom. 2006, 20, 3393.
20. M. Okano, M. Sato, A. Ikekita, S. Kageyama Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24, 2046.
21. A. Thomas, S. Höppner, H. Geyer, W. Schänzer, M. Petrou, D. Kwiatkowska, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 507.
22. A. Pinyot, Z. Nikolovski, J. Bosch, G. Such-Sanmartín, S. Kageyama, J. Segura, et al. Growth hormone secretagogues: out of competition. Anal. Bioanal. Chem. 2012, 402, 1101.
23. M. Okano, A. Ikekita, M. Sato, S. Kageyama Analysis of growth hormone-releasing peptides for doping control, in Recent Advances in Doping Analysis (16), (Eds: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck ). Sportverlag Strauß, Köln, 2008, pp. 223.
24. A. Thomas, M. Kohler, J. Mester, H. Geyer, W. Schänzer, M. Petrou, et al. Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug Test. Anal. 2010, 2, 144.
25. M. Kohler, A. Thomas, H. Geyer, M. Petrou, W. Schänzer, M. Thevis Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test. Anal. 2010, 2, 533.
26. J. Henninge, M. Pepaj, I. Hullstein, P. Hemmersbach Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test. Anal. 2010, 2, 647.
27. J. Henninge, I. Hullstein, P. Hemmersbach Unknown peptide preparations analysed in 2010: An overview, in Recent Advances in Doping Analysis (19), (Eds: W. Schänzer, H. Geyer, A. Gotzmann, U. Mareck ). Sportverlag Strauß, Köln, 2011, pp. 231.
28. K. Walpurgis, A. Thomas, T. Laussmann, L. Horta, S. Metzger, W. Schänzer, et al. Identification of fibroblast growth factor 1 (FGF-1) in a black market product. Drug Test. Anal. 2011, 3, 791.